NEW YORK – Adaptive Biotechnologies and NeoGenomics said Tuesday that they have agreed to a multiyear, exclusive commercial partnership to promote genomic testing for minimal residual disease (MRD) monitoring and personalize treatment in patients with select blood cancers.
Adaptive markets ClonoSeq, a US Food and Drug Administration-cleared sequencing assay designed to detect MRD in lymphoid cancers. NeoGenomics offers a testing service called Compass and Chart, which can include one-time or serial testing using a variety of laboratory and molecular technologies.
Under the terms of the agreement, doctors who order Compass testing for patients with multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma have the option of including a ClonoSeq Clonality test, which identifies patient-specific DNA sequences that can later be used for MRD tracking.
As patients are tested again under NeoGenomics' Chart service, they can then receive ongoing ClonoSeq MRD testing. The companies said this testing will continue to be performed by Adaptive Biotechnologies through its CLIA-certified, CAP-accredited laboratory in Seattle.
In a statement, Adaptive CEO Chad Robins said that the partnership reflects the companies "shared commitment to empowering oncologists and pathologists to deliver the highest quality patient care."
"We are proud of this collaboration, which expands access to the valuable insights that ClonoSeq MRD results offer, ultimately helping more providers and patients benefit from knowing their MRD status," he said.
NeoGenomics CEO Chris Smith added that with MRD testing now recognized as integral to the care of blood cancer patients, offering patients access to ClonoSeq is a way for the company to strengthen its leadership position in hematology testing.
The companies expect to launch cross-promotional efforts later this year. Specific financial terms of the agreement were not disclosed.